Abstract:Tham T Le, 1 Benjamin Emmanuel, 1 Rohit Katial, 2 Trung N Tran, 1 Justin Joseph Kwiatek, 1 David S Cohen, 1 Shoshana R Daniel, 3 Yunhui Cao, 1 Vivian H Shih, 1 Maria Gil Melcón, 4 Gilles Devouassoux, 5 Girolamo Pelaia 6 On behalf of the RANS Study Investigators 1 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA; 2 Center for Clinical Immunology, National Jewish Health & University of Colorado School of Medicine, Denver, CO, USA; 3 Market Access Consulting, Fortrea Inc., Durham, NC, USA; 4 Otorhinolaryngology and Head and Neck Surgery Department, University Hospital of Salamanca, Salamanca, Spain; 5 Department of Pulmonology, Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse, Lyon, and F-CRIN INSERM Network CRISALIS, Toulouse, France; 6 Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy Correspondence: Girolamo Pelaia, University "Magna Graecia" of Catanzaro, Viale Europa, 88100 Catanzaro, Italy, Tel +39 961 3647171, Fax +39 961 3647193, Email Purpose: Real-world evidence of benralizumab effectiveness on nasal polyps (NP) and asthma outcomes in patients with severe eosinophilic asthma (SEA) and comorbid chronic rhinosinusitis with NP are limited. The objective of this study was to assess NP and asthma outcomes in benralizumab-treated patients with SEA and comorbid NP in a real-world setting. Patients and Methods: RANS was a retrospective, multi-country observational study (ClinicalTrials.gov: NCT05180357) using medical chart reviews of adults with SEA and comorbid NP. Total NP Score (NPS), SinoNasal Outcome Test-22 (SNOT-22) total score, annualized exacerbation rate (AER), and 6-item Asthma Control Questionnaire (ACQ-6) and Asthma Control Test (ACT) scores during the 12 months pre-index (baseline) and post-index (follow-up) were measured. Clinically meaningful improvement from baseline following treatment, in terms of total NPS (≥ 1-point reduction), SNOT-22 total (≥ 8.9-point reduction), ACQ-6 (≥ 0.5-point reduction) or ACT (≥ 3-point increase) scores, were reported. Results: A total of 233 patients were included. Baseline mean (standard deviation [SD]) NPS and SNOT-22 total scores were 3.8 (2.4) and 47.5 (22.6), respectively. The mean change (95% confidence interval [CI]) from baseline was – 1.2 (– 1.7, – 0.6) for NPS, and – 19.8 (– 23.6, – 15.9) for SNOT-22. The AER (95% CI) was 1.2 (0.96, 1.41) at baseline and 0.2 (0.13, 0.28) at follow-up. Mean (SD) ACQ-6 and ACT scores were 1.6 (1.3) and 15.0 (5.2) at baseline and 0.8 (1.0) and 22.0 (3.9) at follow-up, respectively. The proportion of patients who achieved clinically meaningful improvements in NPS, SNOT-22 total, ACQ-6, and ACT scores was 49.1%, 67.6%, 56.6%, and 81.1%, respectively. Conclusion: In this real-world study, improvements in NP and asthma outcomes in patients with SEA and comorbid NP were observed during the 12 months following benralizumab initiation. Keywords: exacerbations, comorbidity, biologics, patient-reported outcomes, SinoNasal Outcome Test-22, Nasal Polyps Score Chronic rhinosinusitis with nasal polyps (NP) is one of the most common comorbidities in patients with severe asthma. 1 A combination of NP and severe asthma causes a significant and substantial disease burden on health-related quality of life (HRQoL). 2,3 The management of asthma and comorbid NP is challenging, with patients having a higher risk of asthma exacerbations, and has, therefore, become an area of focus for novel targeted therapies. 2,4 The presence of NP is a strong indicator of the eosinophilic phenotype in severe asthma. 3,5 Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor-α on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis. 6–8 The presence of NP is predictive of a response to benralizumab, including reductions in exacerbations and improvement in lung function. 3,5,9 In a previous Phase III study (OSTRO), benralizumab reduced symptoms and NP Score (NPS) in patients with severe NP who were symptomatic despite intranasal corticosteroid treatment and who had a history of surgery for NPs and/or systemic corticosteroid (SCS) use. 10 Benralizumab also produced meaningful improvements in HRQoL, lung function, and asthma outcomes in patients with severe eosinophilic asthma (SEA) and comorbid NP in the Phase 3b ANDHI study. 11 The effects of benralizumab were enhanced in the subgroup of NP patients who had comorbid asthma in the OS -Abstract Truncated-

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study

A Three-Year Real-Life Study

Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps

Real world effectiveness of benralizumab on respiratory function and asthma control

Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis

Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study

The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

A Three-Year Review of Benralizumab Therapy: Long-Term Control of Eosinophilic Asthma and Associated Risks

Effect of benralizumab on airway mucus, air-trapping and airway volume, assessed by functional respiratory imaging in severe eosinophilic asthma

Early and continued asthma control improvement in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab initiation: real-world XALOC-2 programme

Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma

Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study